- In June 2024, Mycenax partnered with Chitose Laboratory Corp. to develop a new generation of cell lines, focusing on the Supercell supercell line. This collaboration successfully transferred high-yield production clones developed by CHITOSE into the corresponding processes, utilizing its Supercell host, CHO-MK cells
- In July 2022, ProBioGen and Granite Bio announced a collaboration to provide GMP manufacturing and cell line development services. Granite Bio's lead candidate is a novel monoclonal antibody aimed at treating autoimmune and specific cancer indications. The collaboration leverages ProBioGen's DirectedLuck transposase technology, which enhances gene delivery and expression stability, ensuring high-quality and efficient cell line development
- In June 2022, FUJIFILM Corporation announced a significant investment of USD 1.6 billion to enhance and expand the cell culture manufacturing services of its subsidiary, FUJIFILM Diosynth Biotechnologies. This investment aims to bolster the capabilities of FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO), by expanding its sites in Hillerød, Denmark, and Texas, USA. The expansion includes the addition of large-scale bioreactors and downstream processing streams, making the Hillerød facility the largest end-to-end CDMO in Europe. This investment is expected to create approximately 450 jobs and support sustainable production enhancements, aligning with Fujifilm's "Green Value Climate Strategy" to achieve net zero CO2 emissions by the end of Fiscal Year 2040
Frequently Asked Questions
The market is segmented based on Segmentation, By Product (Reagents and Media, Equipment and Accessories, and Consumables), Source (Mammalian Cell Line and Non-Mammalian Cell Line), Cell Line Type (Recombinant Cell Lines, Hybridomas, Continuous Cell Lines, and Primary Cell Lines), Application (Bio Production, Drug Discovery, Toxicity testing, Vaccines, Tissue Engineering, Research, and Others)– Industry Trends and Forecast to 2032
.
The Global Cell Line Development Market size was valued at USD 7.64 USD Million in 2024.
The Global Cell Line Development Market is projected to grow at a CAGR of 7% during the forecast period of 2025 to 2032.
The major players operating in the market include Eurofins Scientific, GENERAL ELECTRIC COMPANY, Lonza, F. Hoffmann-La Roche Ltd, Abbott, bioMérieux SA, Thermo Fischer ScientificInc., Bio-Rad Laboratories. Inc, Danaher, Promega Corporation, Merck KGaA, Sartorius AGCorning Incorporated, Cytovance Biologics, JSR Life SciencesLLC, trenzyme GmbH, MabPlex International Ltd., GenScript, Charles River Laboratories and Abzena Ltd.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
